Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): mechanisms of action and clinical and genetic considerations

References

• Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol. 2010 Apr;9(4):402–412.
   PubMed Web of Science ®Google Scholar
• Broers MC, Bunschoten C, Nieboer D, et al. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Neuroepidemiology. 2019;52(3–4):161–172.
   PubMed Web of Science ®Google Scholar
• Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision. Eur J Neurol. 2021 Nov;28(11):3556–3583.
   PubMed Web of Science ®Google Scholar
• Oaklander AL, Lunn MP, Hughes RA, et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev. 2017 Jan 13;1(1):CD010369.
   PubMedGoogle Scholar
• Lunemann JD, Quast I, Dalakas MC. Efficacy of intravenous immunoglobulin in neurological diseases. Neurotherapeutics. 2016 Jan;13(1):34–46.
   PubMed Web of Science ®Google Scholar
• Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001 Sep 6;345(10):747–755.
   PubMed Web of Science ®Google Scholar
• Malik U, Oleksowicz L, Latov N, et al. Intravenous gamma-globulin inhibits binding of anti-GM1 to its target antigen. Ann Neurol. 1996 Jan;39(1):136–139.
   PubMed Web of Science ®Google Scholar
• Zhang G, Lopez PH, Li CY, et al. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain. 2004 May;127(5):1085–1100.
   PubMedGoogle Scholar
• Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology. 2002 Dec 24;59(12 Suppl 6):S13–21.
   PubMed Web of Science ®Google Scholar
• Jacobs BC, O’Hanlon GM, Bullens RW, et al. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain. 2003 Oct;126(Pt 10):2220–2234.
   PubMedGoogle Scholar
• Buchwald B, Ahangari R, Weishaupt A, et al. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann Neurol. 2002 Jun;51(6):673–680.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Blockade of blocking antibodies in Guillain-Barré syndromes: “unblocking” the mystery of action of intravenous immunoglobulin. Ann Neurol. 2002 Jun;51(6):667–669.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol. 2005 May;252(Suppl 1):I19–25.
   PubMedGoogle Scholar
• Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996 Sep;47(3):678–683.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Spaeth PJ. The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021;14:1756286421997381.
   Web of Science ®Google Scholar
• Querol LA, Hartung HP, Lewis RA, et al. The role of the complement system in chronic inflammatory demyelinating polyneuropathy: implications for complement-targeted therapies. Neurotherapeutics. 2022;19(3):864–873. Apr 4
   PubMed Web of Science ®Google Scholar
• Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1994 Nov;94(5):1729–1735.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther. 2004 Jun;102(3):177–193.
   PubMed Web of Science ®Google Scholar
• Vital C, Vital A, Lagueny A, et al. Chronic inflammatory demyelinating polyneuropathy: immunopathological and ultrastructural study of peripheral nerve biopsy in 42 cases. Ultrastruct Pathol. 2000 Nov-Dec;24(6):363–369.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Inflammatory myopathies Recent advances in pathogenesis and therapy. Adv Neurol. 2002;88:253–271.
   PubMedGoogle Scholar
• Boross P, Arandhara VL, Martin-Ramirez J, et al. The inhibiting Fc receptor for IgG, FcgammaRIIB, is a modifier of autoimmune susceptibility. J Immunol. 2011 Aug 1;187(3):1304–1313.
   PubMed Web of Science ®Google Scholar
• Nandakumar KS, Andren M, Martinsson P, et al. Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcgammaRIIB. Eur J Immunol. 2003 Aug;33(8):2269–2277.
   PubMed Web of Science ®Google Scholar
• Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001 Jan 19;291(5503):484–486.
   PubMed Web of Science ®Google Scholar
• Tackenberg B, Jelčić I, Baerenwaldt A, et al. Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Nat Acad Sci. 2009;106(12):4788.
   PubMed Web of Science ®Google Scholar
• Créange A, Gregson NA, Hughes RAC. Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcγRII expression in patients with chronic inflammatory neuropathies. J Neuroimmunol. 2003;135(1–2):91–95.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med. 2007 Jan 22;204(1):11–15.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006 Aug 4;313(5787):670–673.
   PubMed Web of Science ®Google Scholar
• Merkies IS, Bril V, Dalakas MC, et al. Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study. Neurology. 2009 Apr 14;72(15):1337–1344.
   PubMed Web of Science ®Google Scholar
• Quast I, Keller CW, Maurer MA, et al. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest. 2015 Nov 2;125(11):4160–4170.
   PubMed Web of Science ®Google Scholar
• Murata K, Dalakas MC. Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNAs in chronic inflammatory demyelinating polyneuropathy. Brain. 2000 Aug;123(Pt 8):1660–1666.
   PubMedGoogle Scholar
• Hu W, Janke A, Ortler S, et al. Expression of CD28-related costimulatory molecule and its ligand in inflammatory neuropathies. Neurology. 2007 Jan 23;68(4):277–282.
   PubMed Web of Science ®Google Scholar
• Kieseier BC, Tani M, Mahad D, et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain. 2002 Apr;125(Pt 4):823–834.
   PubMedGoogle Scholar
• Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993 Dec 30;329(27):1993–2000.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. Jama. 2004 May 19;291(19):2367–2375.
   PubMed Web of Science ®Google Scholar
• Amemiya K, Semino-Mora C, Granger RP, et al. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol. 2000 Feb;94(2):99–104.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Update on Intravenous Immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy. Neurotherapeutics. 2021 Oct;18(4):2397–2418.
   PubMed Web of Science ®Google Scholar
• Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain. 2005 Aug;128(Pt 8):1887–1896.
   PubMedGoogle Scholar
• Choi YC, Dalakas MC. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology. 2000 Jan 11;54(1):65–71.
   PubMed Web of Science ®Google Scholar
• Lapointe BM, Herx LM, Gill V, et al. IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain. 2004 Dec;127(Pt 12):2649–2656.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Seow H, Wilson P. Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2006 Dec;11(4):325–329.
   PubMed Web of Science ®Google Scholar
• Latov N, Deng C, Dalakas MC, et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol. 2010 Jul;67(7):802–807.
   PubMedGoogle Scholar
• Kuitwaard K, Hahn AF, Vermeulen M, et al. Intravenous immunoglobulin response in treatment-naive chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2015 Dec;86(12):1331–1336.
   PubMed Web of Science ®Google Scholar
• Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society, European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the european federation of neurological societies and the peripheral nerve society–first revision. J Peripher Nerv Syst. 2010 Mar;15(1):1–9.
   Web of Science ®Google Scholar
• van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988 May;19(5):604–607.
   PubMed Web of Science ®Google Scholar
• Allen JA, Lewis RA. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology. 2015 Aug 11;85(6):498–504.
   PubMed Web of Science ®Google Scholar
• Broers MC, Bunschoten C, Drenthen J, et al. Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2021 Jun;28(6):2065–2073.
   PubMed Web of Science ®Google Scholar
• Bunschoten C, Jacobs BC, Van den Bergh PYK, et al. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019;18(8):784–794.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. IgG4-mediated neurologic autoimmunities. Neurol Neuroimmunol Neuroinflammat. 2021;9:1.
   Google Scholar
• Dalakas MC. Autoimmune neurological disorders with IgG4 antibodies: a distinct disease spectrum with unique IgG4 functions responding to anti-B cell therapies. Neurotherapeutics. 2022 Apr;19(3):741–752.
   PubMed Web of Science ®Google Scholar
• Doneddu PE, Cocito D, Manganelli F, et al. Atypical CIDP: diagnostic criteria, progression and treatment response data from the Italian CIDP database. J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):125–132.
   PubMed Web of Science ®Google Scholar
• Kuwabara S, Isose S, Mori M, et al. Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2015 Oct;86(10):1054–1059.
   PubMed Web of Science ®Google Scholar
• Iijima M, Yamamoto M, Hirayama M, et al. Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology. 2005 Apr 26;64(8):1471–1475.
   PubMed Web of Science ®Google Scholar
• Neligan A, Reilly MM, Lunn MP. CIDP: mimics and chameleons. Pract Neurol. 2014;14(6):399–408.
   PubMedGoogle Scholar
• Verhamme C, Drenthen J. Wanneer is het een block? KNF Dagen, 2017, Lunteren, The Netherlands. Dutch Association for Clinical Neurophysiology; 2017. p. 51–60.
   Google Scholar
• Hauw F, Fargeot G, Adams D, et al. Charcot-Marie-Tooth disease misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: an international multicentric retrospective study. Eur J Neurol. 2021 Sep;28(9):2846–2854.
   PubMed Web of Science ®Google Scholar
• Kuitwaard K, van Doorn PA, Bengrine T, et al. Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2021 May;28(5):1677–1683.
   PubMed Web of Science ®Google Scholar
• Köller H, Kieseier BC, Jander S, et al. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med. 2005;352(13):1343–1356.
   PubMed Web of Science ®Google Scholar
• Alcantara M, Hartung HP, Lawo JP, et al. Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol. 2021 Sep;132(9):2184–2190.
   PubMed Web of Science ®Google Scholar
• Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol. 2009 Nov;66(5):597–603.
   PubMed Web of Science ®Google Scholar
• van Doorn PA, Kuitwaard K, Jacobs BC. Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP. J Peripher Nerv Syst. 2011 Jun;16(Suppl 1):38–40.
   PubMed Web of Science ®Google Scholar
• Iijima M, Koike H, Katsuno M, et al. Polymorphism of transient axonal glycoprotein-1 in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2011 Jun;16(Suppl 1):52–55.
   PubMedGoogle Scholar
• Iijima M, Tomita M, Morozumi S, et al. Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP. Neurology. 2009 Oct 27;73(17):1348–1352.
   PubMed Web of Science ®Google Scholar
• Pang SYY, Chan K-H, Mak WWW, et al. Single-nucleotide polymorphism of transient axonal glycoprotein-1 and its correlation with clinical features and prognosis in chronic inflammatory demyelinating polyneuropathy. J Peripheral Nerv Syst. 2012;17(1):72–75.
   PubMed Web of Science ®Google Scholar
• Voskoboinik I, Trapani JA. Perforinopathy: a spectrum of human immune disease caused by defective perforin delivery or function. Front Immunol. 2013. 12. Dec(4):441.
   Google Scholar
• Voskoboinik I, Whisstock JC, Trapani JA. Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol. 2015 Jun;15(6):388–400.
   PubMed Web of Science ®Google Scholar
• Buttini S, Cappellano G, Ripellino P, et al. Variations of the perforin gene in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Genes Immun. 2015 Jan-Feb;16(1):99–102.
   PubMed Web of Science ®Google Scholar
• Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med. 1999 Jan 21;340(3):227–228.
   PubMed Web of Science ®Google Scholar
• Fokkink WJ, Haarman AE, Tio-Gillen AP, et al. Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS. Ann Clin Transl Neurol. 2016 Jul;3(7):547–551.
   PubMed Web of Science ®Google Scholar
• Vlam L, Cats EA, Willemse E, et al. Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1145–1148.
   PubMed Web of Science ®Google Scholar
• Su S, Liu Q, Zhang X, et al. VNTR2/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis. Ther Adv Neurol Disord. 2021;14:1756286420986747.
   Web of Science ®Google Scholar
• Nagelkerke SQ, Schmidt DE, de Haas M, et al. Genetic variation in low-to-medium-affinity fcgamma receptors: functional consequences, disease associations, and opportunities for personalized medicine. Front Immunol. 2019;10:2237.
   PubMed Web of Science ®Google Scholar
• Schmidt DE, Kmj H-P, Laarhoven AG, et al. Transient and chronic childhood immune thrombocytopenia are distinctly affected by Fc-gamma receptor polymorphisms. Blood Adv. 2019 Jul 9;3(13):2003–2012.
   PubMed Web of Science ®Google Scholar
• Shrestha S, Wiener HW, Olson AK, et al. Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease. J Allergy Clin Immunol. 2011 Sep;128(3):677–680.
   PubMed Web of Science ®Google Scholar
• Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526–536.
   PubMed Web of Science ®Google Scholar
• A study to assess the efficacy, safety and tolerability of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (MyCIDPchoice): NCT03861481 [updated 23 May 2022; cited 2022 June 7]. Available from: https://www.clinicaltrials.gov/ct2/show/results/NCT03861481?term=NCT03861481%2C+Rozanolixizumab&draw=2&rank=1
   Google Scholar
• A study to assess the safety and efficacy of a subcutaneous formulation of efgartigimod in adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE): NCT04281472 [updated 3 May 2022; cited 2022 June 7]. Available from: https://www.clinicaltrials.gov/ct2/results?cond=&term=NCT04281472%3A+Efgartigimod&cntry=&state=&city=&dist=
   Google Scholar
• Cornblath DR, van Doorn PA, Hartung HP, et al. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. Brain. 2022;145(3):887–896. Jan 17
   PubMed Web of Science ®Google Scholar
• Chin RL, Deng C, Bril V, et al. Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: comparison of patients with and without subsequent relapse. Muscle Nerve. 2015 Oct;52(4):498–502.
   PubMed Web of Science ®Google Scholar